Free Trial
ASX:PXS

Pharmaxis (PXS) Stock Price, News & Analysis

Pharmaxis logo

About Pharmaxis Stock (ASX:PXS)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
721,139 shs
Average Volume
N/A
Market Capitalization
A$20.23 million
P/E Ratio
N/A
Dividend Yield
6.41%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive PXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pharmaxis and its competitors with MarketBeat's FREE daily newsletter.

PXS Stock News Headlines

Canaccord Genuity Sticks to Their Buy Rating for Pharmaxis Ltd (SNT)
Pharmaxis Ltd Highlights Product Pipeline and Risks
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).
Syntara bolsters financial position with R&D tax incentive
FIVE at FIVE AU: ASX down 1.5% on Middle East fears; employment slows
Pharmaxis to focus on clinical-stage drug development
See More Headlines

PXS Stock Analysis - Frequently Asked Questions

Pharmaxis Ltd (ASX:PXS) released its quarterly earnings results on Thursday, February, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter. Pharmaxis had a negative net margin of 161.24% and a negative trailing twelve-month return on equity of 143.13%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pharmaxis investors own include Atara Biotherapeutics (ATRA), CRISPR Therapeutics (CRSP), Acasti Pharma (ACST), American Woodmark (AMWD), Guardion Health Sciences (GHSI), Incannex Healthcare (IHL) and XPO (XPO).

Company Calendar

Last Earnings
2/14/2019
Today
8/09/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
Transportation
Current Symbol
ASX:PXS
CIK
N/A
Fax
N/A
Employees
4
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
A($0.02)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
0.21
Net Income
-A$18.43 million
Net Margins
-161.24%
Pretax Margin
N/A
Return on Equity
-143.13%
Return on Assets
-48.68%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
7.21
Quick Ratio
14.73

Sales & Book Value

Annual Sales
A$11.89 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
1.32
Book Value
A$0.00 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
722,610,000
Free Float
N/A
Market Cap
A$20.23 million
Optionable
Not Optionable
Beta
0.64
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

This page (ASX:PXS) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners